NanoViricides is a biotechnology business based in the US. NanoViricides shares (NNVC) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was $1.36 – a decrease of 0.73% over the previous week. NanoViricides employs 7 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.36 |
|---|---|
| 52-week range | $1.00 - $3.59 |
| 50-day moving average | $1.50 |
| 200-day moving average | $1.63 |
| Wall St. target price | $6.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.70 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.34 from 2024-11-22
| 1 week (2024-11-19) | -2.19% |
|---|---|
| 1 month (2024-10-25) | -10.37% |
| 3 months (2024-08-26) | -33.00% |
| 6 months (2024-05-24) | -39.91% |
| 1 year (2023-11-24) | 28.85% |
|---|---|
| 2 years (2022-11-25) | -20.24% |
| 3 years (2021-11-26) | 4.86 |
| 5 years (2019-11-26) | 3.26 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -35.81% |
| Return on equity TTM | -63% |
| Profit margin | 0% |
| Book value | $0.87 |
| Market Capitalization | $18.8 million |
TTM: trailing 12 months
We're not expecting NanoViricides to pay a dividend over the next 12 months.
NanoViricides's shares were split on a 1:20 basis on 23 September 2019 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NanoViricides shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for NanoViricides shares which in turn could have impacted NanoViricides's share price.
Over the last 12 months, NanoViricides's shares have ranged in value from as little as $1.0001 up to $3.59. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while NanoViricides's is 0.968. This would suggest that NanoViricides's shares are less volatile than average (for this exchange).
NanoViricides, Inc. , a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.